

Dermal PBPK Modeling for a Transdermal Delivery System to Assess the Impact of the Application Site on In Vivo Performance

*SBIA 2022: Advancing Generic Drug Development:
Translating Science to Approval*

Day 2, Session 6: Quantitative Methods – Study Design, Model-integrated BE Approaches

Eleftheria Tsakalozou, PhD

Division of Quantitative Methods and Modeling, Office of Research
and Standards

Office of Generic Drugs | CDER | U.S. FDA

September 21, 2022

Disclaimer



This presentation reflects the views of the author and should not be construed to represent FDA's views or policies.



Learning Objectives

- Discuss the general workflow in building and validating a dermal physiologically-based pharmacokinetic (PBPK) model for a transdermal delivery system (TDS);
- Describe the application of the developed model in predicting absorption of an active pharmaceutical ingredient (API) through the skin at an application site other than the one the model was validated for;
- Describe the application of the developed model in predicting the amount of the API remaining in the TDS at the end of the wear period.



Outline


- Transdermal Delivery Systems (TDS)
- In silico methodologies to support drug product development and approval
 - What is dermal Physiologically-based Pharmacokinetic (PBPK) modeling?
- Case Study:
 - Background
 - How was dermal PBPK modeling applied in this case?
 - Model development
 - Model validation
 - Model application
- Take home messages

Transdermal Delivery Systems (TDS)


“... designed to deliver the active ingredient (active substance) across the skin and into systemic circulation...”

- Matrix type TDS: active ingredient(s) dissolved or partially suspended in a mixture of adhesives, penetration enhancers, softeners, and preservatives
- Reservoir type TDS: components in liquid or semi-solid form in a heat-sealed area to entrap the active gel between the backing membrane and a microporous membrane


Matrix type transdermal system




Liquid or gel reservoir type transdermal system



Modeling skin bioavailability...



Mechanistic PBPK models:
API, formulation and human/animal physiology
(variability and population)



API: Active Pharmaceutical Ingredient

Reference Listed Drug (RLD)

- Ethinyl Estradiol (EE); Norelgestromin Transdermal Extended Release Film, 0.035MG/24HR; 0.15MG/24HR
- Estrogen/progestin combination hormonal contraceptive (CHC), indicated for the prevention of pregnancy in women who elect to use a transdermal patch.
- ORTHO EVRA® uses a 28-day (four-week) cycle. Apply a new patch to the upper outer arm, abdomen, buttock or back each week for three weeks (21 total days). Week Four is patch-free.



Mkt.Status	Active Ingredient	Proprietary Name	Appl. No.	Dosage Form	Route	Strength	
RX	ETHINYL ESTRADIOL; NORELGESTROMI N	XULANE	A200910	FILM, EXTENDED RELEASE	TRANSDERMAL	0.035MG/24HR; 0.15MG/24HR	RS
DISCN**	ETHINYL ESTRADIOL; NORELGESTROMI N	ORTHO EVRA	N021180	FILM, EXTENDED RELEASE	TRANSDERMAL	0.035MG/24HR; 0.15MG/24HR	RLD

<https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm>

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

Draft Guidance on Ethinyl Estradiol; Norelgestromin

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Ethinyl estradiol; Norelgestromin

Dosage Form; Route: Film, extended release; transdermal

Recommended Studies: Three studies

1. Type of study: Bioequivalence study with pharmacokinetic endpoints

Design: Single-dose, two-treatment, two-period crossover in vivo

Strength: 0.035 mg/24 hr; 0.15 mg/24 hr

Subjects: Healthy non-pregnant, non-lactating females, who are candidates for hormonal contraception.

Additional comments:

- In this document, this dosage form is referred to as a transdermal delivery system (TDS) and includes products that may be described elsewhere or known as *patches* or *extended release films*.

- Unless otherwise justified, the ethinyl estradiol; norelgestromin TDS should be applied to the same anatomical site on all subjects, selected from among those recommended for dosing in the approved labeling for the reference product, and worn for 7 days. Applicants should randomize subjects to receive either the test or reference product in a given study period. When possible, the TDS administered in the second study period should be applied to the same anatomical site as in the first study period, but on the contralateral side of the body.

Case Study: Background

- A generic TDS (Test) was developed with API loaded amount that was lower than the respective API amount in the Reference Standard (RS).
- Bioequivalence (BE) was demonstrated between the RS and Test products following TDS application to the abdomen in agreement with the current product-specific guidance (PSG) recommendations.
- Literature reports no impact of anatomical site on the EE systemic exposure following application of the RLD.




Figure 2 Mean serum concentration vs time profile of ethinyl oestradiol (EE) following successive applications of the contraceptive patch for 7 days at each of the four anatomical sites (● abdomen; ▲ arm; ■ buttock; ○ torso). Dashed horizontal lines indicate reference range.

Br J Clin Pharmacol 2002 Feb;53(2):141-6. Abrams et al..

Case Study: Question

What is the impact of the application site on the API amount delivered into the systemic circulation over the TDS application period and can it result in dose depletion when the API loaded amount differs between the RS and the Test products?




The Agency internally used Modeling and Simulation approaches to assess the potential need for conducting an in vivo BE study with PK endpoints in female healthy volunteers with back as the application site.



Model Assumptions

- TDS releases API at the same rate regardless of the application site, which is consistent with the current knowledge of TDS function. Differences in PK exposure following application at different application sites would be the result of differences in skin physiology between application sites.
- Parameters contributing to variability besides application site include number of subjects, study-to-study differences in skin physiology and drug distribution and elimination, and study conduct (e.g., how TDS was applied and conditions at which TDS was applied).
- Potential impact of adhesion on drug product performance is beyond the scope of this work and was not consider here.

Model Development and Validation Workflow




Model Development

- Systemic disposition model for intravenously administered EE:
 - EE physicochemical parameters and PK characteristics used for the development of the systemic disposition model
 - Literature (Ezuruike et al, 2018, Drugbank, PubChem)
 - Validation: Back et al.,1987 and in-house data
- Dermal PBPK model developed for EE applied as a TDS
 - QSAR models except diffusion in viable epidermis and dermis which were optimized against systemic PK data for the TDS
 - Validation: literature, in-house data
- EE release from the TDS was empirically obtained by deconvoluting the systemic PK data
 - Methods that mechanistically model API release from the TDS did not perform well

Application Site: Abdomen





- The “abdomen” was not available as an application site within the modeling platform used
- Development and validation of the “abdomen” as an application site leveraging RLD data



RLS: Reference Listed Drug, PI: prediction interval

Parameter	Value (CV%) males/females	Source
Stratum corneum, skin surface pH	5.29 (10%)/5.98 (10%)	Bailey et al.,2012
Viable epidermis, thickness (µm)	99.8 (50%)	Wei et al., 2017
Dermis, thickness (µm)	2284 (50.1%)	Wei et al., 2017
Subcutis, thickness (µm)	17 (30%)/22 (30%)	Derraik et al., 2014, Lancerotto et al.,2011
Muscle, thickness (µm)	8 (30%)/4 (30%)	Tanah et al., 2016

Acceptable Model Performance



The dermal PBPK model was validated against literature and in-house data on the systemic API exposure.

- Dose proportionality study: range of application areas for TDS
- Steady state (cycle 1-3) vs single dose
- Over the time period of 3 weeks
- Across different studies


PI: prediction interval

Exposure Following Application on the Back was Predicted



The validated model for the RLD was used to:



- develop dermal PBPK models for the RS and the Test product.
- predict API exposure following application for the Test product on the anatomical site developed and assess the risk for dose depletion at the end of the application period.
- EE release rate obtained by deconvoluting systemic PK data for the Test product (abdomen site).



VBE assessment between the Test and RS



- Test and RS are expected to be bioequivalent leveraging the developed models within the scope of a virtual bioequivalence (VBE) assessment.
- No EE depletion is expected for the Test drug product when the product is applied on the back of healthy volunteers under the labeled use conditions.



Conclusion

The validated dermal PBPK model was used to predict the API exposure following TDS application to an anatomical site other than the one evaluated in the in vivo BE study with PK endpoints and to assess the potential for API depletion during the application period.

- Modeling and simulation approaches with a VBE assessment component can be used to support product development and approval for transdermal and dermatological drug products.
 - Provide insight on the effect of important formulation attributes that may influence skin permeation of the API
- Modeling and simulation approaches coupled with a VBE assessment supporting an Abbreviated New Drug Application (ANDA):
 - Early interaction between industry and regulatory agency should be initiated through the pre-ANDA meeting request program, GDUFA II.¹

Generic Drug User Fee Amendments: Regulatory Science/Research



Grant	Grant Duration	Institute	Grant No.
Development and validation of dermal PBPK modelling platform towards virtual bioequivalence assessment considering population variability	2014-2018	Simcyp, Ltd	1U01FD005225
Physiologically based biopharmaceutics and pharmacokinetics of drug products for dermal absorption in humans	2014-2019	University of South Australia	1U01FD005232
Characterization of key system parameters of mechanistic dermal PBPK models in various skin diseases and performance verification of the model using observed local and systemic concentrations	2018-2020	Simcyp, Ltd	1U01FD006521
Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations	2018-2020	SimulationsPlus, Inc	1U01FD006526
Formulation drug product quality attributes in dermal physiologically-based pharmacokinetic models for topical dermatological drug products and transdermal delivery systems	2018-2020	University of Queensland	1U01FD006522
PBPK and Population Modeling Seamlessly Linked to Clinical Trial Simulation in an Open-Source Software Platform	2018-2021	Children's Hospital of Los Angeles	1U01FD006549
Progressing integration of in vitro topical formulation characterisation, release and permeation data to the next level - PBPK based extrapolation to bioequivalence assessment in virtual populations	2021-2023	Certara UK,Ltd	1U01FD007323
Dermal Drug Product Quality and Bioequivalence Assessment through Advanced MAM and PBPK Simulation	2021-2023	SimulationsPlus, Inc	1U01FD007320
Quantitative Expression and Inter-Individual Variability of Skin Proteins Involved in Drug and Excipient Metabolism and Transporters Using Targeted and Label Free LC MS/MS Proteomics	2021-2023	University of Manchester	1U01FD007348

Acknowledgments

FDA/CDER

OGD/ORS/DQMM

Andrew Babiskin
Lucy Fang
Liang Zhao

Khondoker Alam
Ross Walenga
Mingliang Tan

OGD/ORS/DTP I

Priyanka Ghosh
Markham Luke

OGD/ORS-IO

Lei Zhang
Robert Lionberger
Sam Raney



www.fda.gov/GDUFARegScience

Questions?

Eleftheria Tsakalozou, PhD

Eleftheria.Tsakalozou@fda.hhs.gov

Division of Quantitative Methods and Modeling
Office of Research and Standards, Office of Generic Drugs
CDER | U.S. FDA

Challenge Question

What are the key elements of the model development and validation workflow presented here:

- A. Systemic Disposition Model for EE
- B. In vivo EE release kinetics from the TDS
- C. Dermal PBPK model for EE TDS
- D. Model validation and refinement
- E. All of the above



U.S. FOOD & DRUG
ADMINISTRATION